NYMOX PHARMACEUTICAL CORP
NYMXF evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NYMXF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NYMXF
NYMOX PHARMACEUTICAL CORP is a development-stage biopharmaceutical company focused on therapeutic products, with its lead candidate fexapotide triflutate (NX-1207) for benign prostatic hyperplasia (BPH) having faced Phase 3 clinical setbacks and ongoing development uncertainty.
Key risk: Clinical trial failure risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2024.
Tracking 28 clinical trials · 5 catalysts for NYMOX PHARMACEUTICAL CORP.
NYMOX PHARMACEUTICAL CORP is a development-stage biopharmaceutical company focused on therapeutic products, with its lead candidate fexapotide triflutate (NX-1207) for benign prostatic hyperplasia (BPH) having faced Phase 3 clinical setbacks and ongoing development uncertainty.
- Lead candidate NX-1207 (fexapotide triflutate) for BPH failed to meet primary endpoints in Phase 3 trials at 12 months post-treatment as of November 2014 [sec · filed 2024-08-29].
- The company has no revenues from product sales; net loss was $8.84 million for the year ended December 31, 2023 [sec · filed 2024-08-29].
- Shareholders' equity was negative $3.2 million as of December 31, 2024 [sec].
- Research and development expenditures are expected to decrease due to reduced U.S. BPH trial activity pending data evaluation [sec · filed 2024-08-29].
- The company has historically relied on equity financings to fund operations and may seek additional financing if liquidity needs change [sec · filed 2025-06-03].
What works
- The company has ongoing clinical development programs with multiple Phase 3 trials planned or underway for NX-1207, as indicated by catalyst timelines extending to 2031 [upcoming catalysts].
- Management actively manages liquidity to minimize shareholder dilution and has a history of securing financing through private placements and collaboration agreements [sec · filed 2023-05-02].
What to weigh
- NX-1207 failed to show statistical significance versus placebo in Phase 3 BPH trials at 12 months, leading to development delays and uncertainty about regulatory approval [sec · filed 2024-08-29].
- The company has no product revenues and has incurred net losses, with an accumulated deficit and negative shareholders' equity as of December 31, 2024 [sec].
- Clinical trial timelines are highly uncertain; the company states it is impossible to outline the nature, timing, or estimated costs to complete R&D projects due to inherent risks [sec · filed 2025-06-03].
- The company may need additional financing to fund operations over the next 12 months, and if not obtained, could face liquidity challenges [sec · filed 2025-06-03].
From the filings
Quoted directly from source documents.
Phase 3 trials of NX-1207 for BPH failed to meet primary endpoints at 12 months.
“On November 2, 2014, following the completion of data verification and auditing procedures, top-line results of the Phase 3 NX02-0017 and NX02-0018 U.S. clinical trials of NX-1207 for BPH at 12 months post-treatment were not statistically significant compared to placebo.”
SEC filings · August 29, 2024
The company has no revenues from product sales.
“Revenues from sales of goods were nil for the year ended December 31, 2023 and 2022.”
SEC filings · August 29, 2024
The company cannot reasonably estimate the costs or timing to complete R&D projects.
“Because of the early stage of development and the uncertainty related to the Corporation's R&D projects, it is impossible to outline the nature, timing or estimated costs of the efforts necessary to complete these projects, nor the anticipated completion dates for these projects.”
SEC filings · June 3, 2025
The company may need additional financing to fund operations.
“from product sales are not sufficient to fund substantially all its planned business operations and research and development programs over next 12 months. However, if necessary, the Company intends to seek additional equity or other financing, should the Company's liquidity needs change.”
SEC filings · June 3, 2025
Catalyst timeline
- 2026-10-29 · Phase 3 Topline: A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Trial to Evalua — First upcoming Phase 3 topline data readout for NX-1207; results will be a key indicator of clinical efficacy.
- 2027-06-30 · Phase 3 Topline: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy an — Second Phase 3 topline readout; may provide additional efficacy and safety data.
- 2028-01-31 · Phase 3 Topline: A Phase Ⅲ Randomized, Parallel-group, Placebo-controlled Trial to Assess the Efficacy, Safety of the — Third Phase 3 topline readout; further data on the product candidate's profile.
- 2028-10-01 · Phase 3 Topline: A Multicenter, Randomized, Double-blind, Active-Controlled, Parallel, Phase Ⅲ Study to Evaluate the — Fourth Phase 3 topline readout; includes active comparator arm.
- 2031-01-01 · Phase 3 Topline: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Anti-Tumo — Longest-dated Phase 3 topline readout; may indicate a different indication or extended timeline.
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — NX-1207 failed Phase 3 endpoints; future trials may also fail to demonstrate efficacy or safety [sec · filed 2024-08-29].
- No revenue and negative equity — No product sales, net losses, and negative shareholders' equity of -$3.2M as of 2024-12-31 [sec].
- Liquidity and financing risk — Cash from operations insufficient for 12 months; may need additional equity or debt financing [sec · filed 2025-06-03].
- Regulatory and development delays — Uncertainty in clinical timelines; delays common and could impact milestones [sec · filed 2025-06-03].
What to watch
- Upcoming Phase 3 topline data readouts for NX-1207, with the earliest expected around October 2026 [upcoming catalysts].
- Any new financing arrangements or equity offerings to address liquidity needs [sec · filed 2025-06-03].
- Regulatory feedback or trial design changes following the prior Phase 3 failure [sec · filed 2024-08-29].
- Changes in R&D expenditure levels as U.S. BPH trial activity is reduced [sec · filed 2024-08-29].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run NYMOX PHARMACEUTICAL CORP through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NYMOX PHARMACEUTICAL CORP facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Cash runway data unavailable
N/A
No tracked pipeline phase
No tracked pipeline candidates
5 upcoming, next in ~60d
No insider transactions in the last 180 days
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$2K
| Holder | Shares | Value |
|---|---|---|
| first citizens financial corp | 35,100 | $2K |
Short Interest
as of Apr 22, 2026- % of float
- 4.7%
- Days to cover
- 59.7
- Shares short
- 2,033,620
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NYMXF short interestFrequently asked questions
What is the AI investment thesis for NYMOX PHARMACEUTICAL CORP?
NYMOX PHARMACEUTICAL CORP is a development-stage biopharmaceutical company focused on therapeutic products, with its lead candidate fexapotide triflutate (NX-1207) for benign prostatic hyperplasia (BPH) having faced Phase 3 clinical setbacks and ongoing development uncertainty.
What is NYMOX PHARMACEUTICAL CORP's next catalyst?
NYMOX PHARMACEUTICAL CORP's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Trial to Evalua" — expected October 29, 2026.
Who is the CEO of NYMOX PHARMACEUTICAL CORP?
Dr. Paul Averback DABP, M.D. is the chief executive officer of NYMOX PHARMACEUTICAL CORP (NYMXF).
Where is NYMOX PHARMACEUTICAL CORP headquartered?
NYMOX PHARMACEUTICAL CORP (NYMXF) is headquartered in Nassau, Bahamas.
What therapeutic areas does NYMOX PHARMACEUTICAL CORP focus on?
NYMOX PHARMACEUTICAL CORP develops therapies across Oncology, Rare Disease, Neurology, Immunology, Ophthalmology, Cardiovascular, Infectious Disease, Metabolic, Respiratory, Dermatology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.